CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance

Despite wide use of anti-vascular endothelial growth factor (VEGF) therapy for many solid cancers, most individuals become resistant to this therapy, leading to disease progression. Therefore, new biomarkers and strategies for blocking adaptive resistance of cancer to anti-VEGF therapy are needed. A...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell reports (Cambridge) Jg. 36; H. 7; S. 109549
Hauptverfasser:	Ma, Shaolin, Mangala, Lingegowda S., Hu, Wen, Bayaktar, Emine, Yokoi, Akira, Hu, Wei, Pradeep, Sunila, Lee, Sanghoon, Piehowski, Paul D., Villar-Prados, Alejandro, Wu, Sherry Y., McGuire, Michael H., Lara, Olivia D., Rodriguez-Aguayo, Cristian, LaFargue, Christopher J., Jennings, Nicholas B., Rodland, Karin D., Liu, Tao, Kundra, Vikas, Ram, Prahlad T., Ramakrishnan, Sundaram, Lopez-Berestein, Gabriel, Coleman, Robert L., Sood, Anil K.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Elsevier Inc 17.08.2021 Elsevier
Schlagworte:	Aged angiogenesis Animals BASIC BIOLOGICAL SCIENCES bevacizumab Bevacizumab - pharmacology Bevacizumab - therapeutic use CD63 Cell Line, Tumor Cell Proliferation Disease Models, Animal drug resistance Extracellular vesicles Extracellular Vesicles - metabolism Extracellular Vesicles - ultrastructure Female Humans Mice Mice, Nude Middle Aged Neovascularization, Pathologic - metabolism Neovascularization, Pathologic - pathology Ovarian Neoplasms - drug therapy Protein Isoforms - metabolism Signal Transduction Tetraspanin 30 - metabolism Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular Endothelial Growth Factor A - metabolism Vascular Endothelial Growth Factor Receptor-2 - metabolism VEGF bevacizumab CD63 extracellular vesicles drug resistance VEGF angiogenesis
ISSN:	2211-1247, 2211-1247
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!